TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy Of Multiparametric Telemonitoring On Respiratory Outcomes In Elderly People With Chronic Obstructive Pulmonary Disease.
Brief Summary: Chronic obstructive pulmonary disease (COPD) determines an important risk of disability and disease-related need of care. Selected interventions were able to reduce the number and the severity of exacerbations. Telemedicine has also been proposed for this purpose. Current evidences, however, are scant. The investigators present a randomized, parallel-group trial of a multiparametric remote monitoring system to test its ability to improve early exacerbation detection rates and impact on clinical outcomes.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention
B: Arm Label: TREATMENT Group; Type: ACTIVE_COMPARATOR; Interventions: Device: HF Pressure Measurement System | Arm Label: CONTROL Group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: HF Pressure Measurement System; Assigned to Arm(s): TREATMENT Group
C: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
D: Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Procedure: Telemonitoring | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy Of Multiparametric Telemonitoring On Respiratory Outcomes In Elderly People With Chronic Obstructive Pulmonary Disease.
Brief Summary: Chronic obstructive pulmonary disease (COPD) determines an important risk of disability and disease-related need of care. Selected interventions were able to reduce the number and the severity of exacerbations. Telemedicine has also been proposed for this purpose. Current evidences, however, are scant. The investigators present a randomized, parallel-group trial of a multiparametric remote monitoring system to test its ability to improve early exacerbation detection rates and impact on clinical outcomes.


Options:
A: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
B: Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Procedure: Telemonitoring | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self monitoring for patients with COPD; Type: EXPERIMENTAL; Interventions: Procedure: self-monitoring for patients with severe COPD | Arm Label: Nurse monitoring for patients with COPD; Type: EXPERIMENTAL; Interventions: Procedure: nurse-monitoring for patients with severe COPD | Intervention Type: PROCEDURE; Name: self-monitoring for patients with severe COPD; Assigned to Arm(s): Self monitoring for patients with COPD | Intervention Type: PROCEDURE; Name: nurse-monitoring for patients with severe COPD; Assigned to Arm(s): Nurse monitoring for patients with COPD
D: Arm Label: Inpatient hospitalization; Type: ACTIVE_COMPARATOR; Interventions: Other: Inpatient Hospitalization | Arm Label: Home hospitalization; Type: EXPERIMENTAL; Interventions: Other: Home hospitalization | Intervention Type: OTHER; Name: Home hospitalization; Assigned to Arm(s): Home hospitalization | Intervention Type: OTHER; Name: Inpatient Hospitalization; Assigned to Arm(s): Inpatient hospitalization

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients
Brief Summary: Previous research regarding the use of phenylephrine has excluded obese subjects (BMI \>35). This subgroup of patients represents a large portion of the obstetric patient population locally and nationally. It is unclear whether previous research should be extrapolated to the obese patient population. This study is being done to compare the incidence of hypotension, intraoperative nausea and vomiting, and neonatal acidosis between obese patients who receive a prophylactic phenylephrine infusion versus those who receive phenylephrine boluses for the treatment of established hypotension. This study will help us determine whether using a phenylephrine infusion or a phenylephrine bolus is the best way to prevent/treat spinal induced hypotension during cesarean deliveries in obese patients.


Options:
A: Arm Label: Metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide | Arm Label: Phenylephrine infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Phenylephrine infusion | Arm Label: Combination Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination Group | Intervention Type: DRUG; Name: Metoclopramide; Assigned to Arm(s): Metoclopramide | Intervention Type: DRUG; Name: Phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion | Intervention Type: DRUG; Name: Combination Group; Assigned to Arm(s): Combination Group
B: Arm Label: Exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Exteriorization of the uterus | Arm Label: Non exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Non exteriorization of the uterus | Intervention Type: PROCEDURE; Name: Repair of uterine incision; Assigned to Arm(s): Exteriorization group, Non exteriorization group | Intervention Type: PROCEDURE; Name: Exteriorization of the uterus; Assigned to Arm(s): Exteriorization group | Intervention Type: PROCEDURE; Name: Non exteriorization of the uterus; Assigned to Arm(s): Non exteriorization group
C: Arm Label: Phenylephrine bolus; Type: EXPERIMENTAL; Interventions: Drug: Phenylephrine bolus | Arm Label: Phenylephrine infusion; Type: EXPERIMENTAL; Interventions: Drug: phenylephrine infusion | Intervention Type: DRUG; Name: Phenylephrine bolus; Assigned to Arm(s): Phenylephrine bolus | Intervention Type: DRUG; Name: phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion
D: Arm Label: Irrigation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Normal Saline Irrigation | Arm Label: No Irrigation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Normal Saline Irrigation; Assigned to Arm(s): Irrigation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
Brief Summary: The clinical benefits of sunitinib and sorafenib have been demonstrated in patients with cytokine-refractory metastatic renal cell carcinoma. Sunitinib has also been shown to improve progression free survival and overall survival in a comparative study with interferon-alpha. When sunitinib is used as first-line molecular-targeted therapy, switching to sorafenib is one of the treatment options after disease progression. Reversely, when sorafenib is used as first-line molecular-targeted therapy, sunitinib is used as second-line therapy. The goal of cancer treatment is cure, and if cure is not possible, it is to prolong survival. In this study, sunitinib or sorafenib will be administered as first-line molecular-targeted therapy and treatment switched to the other test drug, sorafenib or sunitinib, when disease progression is detected to assess which treatment sequence produces longer progression free survival and offers a better safety profile (causing fewer adverse events). The purpose of this trial is to compare progression free survival of first line sunitinib versus sorafenib, and that of two treatment sequences, i.e. sunitinib followed by sorafenib versus sorafenib followed by sunitinib.


Options:
A: Arm Label: Tivozanib hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib hydrochloride | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Tivozanib hydrochloride; Assigned to Arm(s): Tivozanib hydrochloride | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
B: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
C: Arm Label: Sorafenib-sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib-sunitinib | Arm Label: Sunitinib-sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib-sorafenib | Intervention Type: DRUG; Name: Sorafenib-sunitinib; Assigned to Arm(s): Sorafenib-sunitinib | Intervention Type: DRUG; Name: Sunitinib-sorafenib; Assigned to Arm(s): Sunitinib-sorafenib
D: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Technology to Prevent Obesity Among African American Girls
Brief Summary: The purpose of this project is to reduce health disparities in obesity risk among 8-10 year old African American girls using a culturally sensitive and developmentally appropriate internet-based program with no face-to-face interaction. This study will conduct an outcome evaluation to test short and longer term effects on obesity risk.


Options:
A: Arm Label: story plus behaviorial procedures; Type: EXPERIMENTAL; Interventions: Behavioral: Food, Fun, & Fitness Internet Program for Girls | Arm Label: story only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Food, Fun, & Fitness Internet Program for Girls | Arm Label: Wait list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Food, Fun, & Fitness Internet Program for Girls; Assigned to Arm(s): story only, story plus behaviorial procedures
B: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A
C: Arm Label: CHL program; Type: EXPERIMENTAL; Interventions: Other: CHL program | Arm Label: Delayed Optimized CHL program; Type: OTHER; Interventions: Other: Delayed Optimized CHL program | Arm Label: Temporal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHL program; Assigned to Arm(s): CHL program | Intervention Type: OTHER; Name: Delayed Optimized CHL program; Assigned to Arm(s): Delayed Optimized CHL program
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Detection and Intervention on Mild/Moderate Chronic Obstructive Pulmonary Disease by Traditional Chinese Medicine Treatment and Application
Brief Summary: The purpose of this study is to compare the exercise capacity and pulmonary function test parameters of Chronic Obstructive Pulmonary Disease (COPD) patients who underwent usual care with and without pulmonary daoyin therapy of China in community.


Options:
A: Arm Label: QualiCCare education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: active comparator, QualiCCare education | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: active comparator, QualiCCare education; Assigned to Arm(s): QualiCCare education
B: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES
C: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
D: Arm Label: Pulmonary daoyin therapy of China; Type: EXPERIMENTAL; Interventions: Other: Pulmonary daoyin therapy of China | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: OTHER; Name: Pulmonary daoyin therapy of China; Assigned to Arm(s): Pulmonary daoyin therapy of China | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)
Brief Summary: Patients with deep vein thrombosis (DVT) of the ilio-femoral veins have increased risk for developing post-thrombotic syndrome (PTS) and recurrent venous thromboembolism compared to more distal DVT. There's evidence that the early removal of the obstructing thrombus by catheter directed thrombolysis (CDT) reduces the risk of developing a PTS, and a higher degree of thrombolysis is associated with lower incidence of PTS, better quality of life and lower risk of recurrent venous thromboembolism. A further development is ultrasound-enhanced thrombolysis combining CDT with a sophisticated catheter system that employs high-frequency, low-dose ultrasound. In vitro experiments showed that adding ultrasound to thrombolytic drugs accelerates thrombolysis while Ultrasound exposure alone results in no thrombolysis, however the superiority of ultrasound-enhanced thrombolysis over standard CDT has never been formally assessed in vivo. The hypothesis for this study is that ultrasound-enhanced thrombolysis reaches a higher degree of thrombolysis than standard CDT in patients with symptomatic ilio-femoral DVT.


Options:
A: N/A
B: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
C: Arm Label: Intermediate dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: intermediate dose Enoxaparin/ unfractionated heparin | Arm Label: Standard Prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin | Arm Label: Atorvastatin 20; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin 20mg | Arm Label: Atorvastatin 20 mg Matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched placebo | Intervention Type: DRUG; Name: intermediate dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Intermediate dose anticoagulation | Intervention Type: DRUG; Name: standard prophylactic dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Standard Prophylaxis | Intervention Type: DRUG; Name: Atorvastatin 20mg; Assigned to Arm(s): Atorvastatin 20 | Intervention Type: DRUG; Name: Matched placebo; Assigned to Arm(s): Atorvastatin 20 mg Matched placebo
D: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)
Brief Summary: Patients with deep vein thrombosis (DVT) of the ilio-femoral veins have increased risk for developing post-thrombotic syndrome (PTS) and recurrent venous thromboembolism compared to more distal DVT. There's evidence that the early removal of the obstructing thrombus by catheter directed thrombolysis (CDT) reduces the risk of developing a PTS, and a higher degree of thrombolysis is associated with lower incidence of PTS, better quality of life and lower risk of recurrent venous thromboembolism. A further development is ultrasound-enhanced thrombolysis combining CDT with a sophisticated catheter system that employs high-frequency, low-dose ultrasound. In vitro experiments showed that adding ultrasound to thrombolytic drugs accelerates thrombolysis while Ultrasound exposure alone results in no thrombolysis, however the superiority of ultrasound-enhanced thrombolysis over standard CDT has never been formally assessed in vivo. The hypothesis for this study is that ultrasound-enhanced thrombolysis reaches a higher degree of thrombolysis than standard CDT in patients with symptomatic ilio-femoral DVT.


Options:
A: Arm Label: Intervention arm: intermediate-dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Heparin Infusion, Drug: Enoxaparin/Lovenox Intermediate Dose | Arm Label: Control arm: prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin Prophylactic Dose, Drug: Heparin SC | Intervention Type: DRUG; Name: Enoxaparin Prophylactic Dose; Assigned to Arm(s): Control arm: prophylaxis | Intervention Type: DRUG; Name: Heparin Infusion; Assigned to Arm(s): Intervention arm: intermediate-dose anticoagulation | Intervention Type: DRUG; Name: Heparin SC; Assigned to Arm(s): Control arm: prophylaxis | Intervention Type: DRUG; Name: Enoxaparin/Lovenox Intermediate Dose; Assigned to Arm(s): Intervention arm: intermediate-dose anticoagulation
B: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A
C: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)
Brief Summary: Patients with deep vein thrombosis (DVT) of the ilio-femoral veins have increased risk for developing post-thrombotic syndrome (PTS) and recurrent venous thromboembolism compared to more distal DVT. There's evidence that the early removal of the obstructing thrombus by catheter directed thrombolysis (CDT) reduces the risk of developing a PTS, and a higher degree of thrombolysis is associated with lower incidence of PTS, better quality of life and lower risk of recurrent venous thromboembolism. A further development is ultrasound-enhanced thrombolysis combining CDT with a sophisticated catheter system that employs high-frequency, low-dose ultrasound. In vitro experiments showed that adding ultrasound to thrombolytic drugs accelerates thrombolysis while Ultrasound exposure alone results in no thrombolysis, however the superiority of ultrasound-enhanced thrombolysis over standard CDT has never been formally assessed in vivo. The hypothesis for this study is that ultrasound-enhanced thrombolysis reaches a higher degree of thrombolysis than standard CDT in patients with symptomatic ilio-femoral DVT.


Options:
A: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
B: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
C: Arm Label: LMWH; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparine calcium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: nadroparine calcium; Assigned to Arm(s): LMWH | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1; Type: N/A; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Group 2; Type: N/A; Interventions: Drug: Standard of care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Group 2

Answer: A